# Involvement of Secondary Induced Thrombus on Hemorrhage Induced by Both Delayed Recanalization and Delayed t-PA Treatment in Murine Ischemic Stroke Models

**Authors:** Yuhki Moriike, Yumeta Nakano, Yasuki Matano, Yasuhiro Suzuki, Kazuo Umemura, Nobuo Nagai

PMC · DOI: 10.3390/biomedicines14020308 · Biomedicines · 2026-01-29

## TL;DR

This study explores how delayed treatment of stroke can lead to bleeding in mice, and suggests that preventing secondary blood clots may reduce this risk.

## Contribution

The study introduces novel murine stroke models and identifies secondary thrombus formation as a key mechanism in delayed treatment-induced hemorrhage.

## Key findings

- Delayed reperfusion in stroke models leads to secondary thrombus formation.
- Heparin pretreatment reduces hemorrhage by inhibiting thrombus formation.
- MMP-9 activity is localized to the secondary thrombus site.

## Abstract

Background: In the treatment of ischemic stroke, both tissue-type plasminogen activator (t-PA) thrombolytic and endovascular therapy are employed; however, delayed intervention with these therapies increases the risk of hemorrhage. Hemorrhage associated with delayed t-PA treatment involves the activation of plasmin and matrix metalloproteinases (MMPs); however, the detailed mechanisms underlying I/R activation remain unclear. Objectives: This study examined the effects of delayed recanalization on ischemic stroke in a permanent middle cerebral artery (MCA) occlusion (MCA-O) model, and a novel MCA ischemia/reperfusion (I/R) model: 2-h ischemia followed by reperfusion (I/R 2 h), and 4.5-h ischemia followed by reperfusion (I/R 4.5 h). Secondary induced thrombus (SIT) formation, hemorrhage, MMP activity, MMP-9 immunoreactivity, and tomato lectin (TL) staining, as well as the effects of t-PA and heparin treatment were evaluated. Results: SIT formed within 1 h after reperfusion in the I/R 4.5 h model only, while t-PA or heparin treatment reduced SIT formation. Hemorrhage increased with or without t-PA administration in the I/R 4.5 h model, but it was suppressed by heparin pretreatment. MMP activity and MMP-9 immunoreactivity were localized to the SIT. Additionally, a negative staining area for TL was observed in the damaged area, where SIT formed in the I/R 4.5 h model. Conclusions: These results suggest that delayed recanalization induces SIT via glycocalyx degradation, leading to hemorrhage via plasmin/MMP-9 activation by endogenous and exogenous t-PA-mediated fibrinolysis in novel murine models of ischemic stroke. Furthermore, inhibition of SIT formation is beneficial for suppressing hemorrhages associated with delayed recanalization after endovascular or t-PA therapy.

## Linked entities

- **Proteins:** PLAT (plasminogen activator, tissue type), MMP9 (matrix metallopeptidase 9), plg (plasminogen)
- **Diseases:** ischemic stroke (MONDO:1060198)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Rsph1 (radial spoke head 1 homolog (Chlamydomonas)) [NCBI Gene 22092] {aka MCA, Tsga2}, PLAT (plasminogen activator, tissue type) [NCBI Gene 5327] {aka T-PA, TPA}, Serpinc1 (serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1) [NCBI Gene 11905] {aka ATIII, At-3, At3}, Serpind1 (serine (or cysteine) peptidase inhibitor, clade D, member 1) [NCBI Gene 15160] {aka HC-II, HCII, Hcf2}, Mmp3 (matrix metallopeptidase 3) [NCBI Gene 17392] {aka EMS-2, MMP-3, SL-1, SLN-1, SLN1, STR-1}, Sit1 (suppression inducing transmembrane adaptor 1) [NCBI Gene 54390] {aka Sit}, Hyal1 (hyaluronoglucosaminidase 1) [NCBI Gene 15586] {aka Fus2, Hya1, Hyal-1, Nat6}, Plg (plasminogen) [NCBI Gene 18815] {aka Pg}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}
- **Diseases:** ischemia (MESH:D007511), necrosis (MESH:D009336), -O (MESH:C535508), neuronal cell damage (MESH:D009410), Bleeding (MESH:D006470), occlusion of cerebral blood vessels (MESH:D009383), Infarct (MESH:D007238), stroke (MESH:D020521), Cerebral Infarction (MESH:D002544), vessel occlusion (MESH:C536223), MCA-I/R (MESH:D002545), cerebrovascular disorders (MESH:D002561), inflammation (MESH:D007249), injury to (MESH:D014947), SIT (MESH:D013927), vascular occlusion (MESH:D008641), MCA occlusion (MESH:D020244), Brain damage (MESH:D001925)
- **Chemicals:** biotin (MESH:D001710), Heparin (MESH:D006493), paraform aldehyde (MESH:C003043), isoflurane (MESH:D007530), Dex (MESH:D003915), I (MESH:D007455), FITC (MESH:D016650), N-acetylglucosamine (MESH:D000117), Cy3 (-), Dextran (MESH:D003911), glycosaminoglycans (MESH:D006025), sugar (MESH:D000073893), 2,3,5-triphenyltetrazolium chloride (MESH:C009591)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** /c — Mus musculus (Mouse), Hepatocellular carcinoma of the mouse, Cancer cell line (CVCL_9103)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938425/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938425/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938425/full.md

---
Source: https://tomesphere.com/paper/PMC12938425